Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), Shenzhen Hepalink Pharmaceutical Group Co's 3-1 Month Momentum % is N/A%.
SHEZF's 3-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: -5.26 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Shenzhen Hepalink Pharmaceutical Group Co 3-1 Month Momentum % Related Terms
SHEZF vs ZTS: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shenzhen Hepalink Pharmaceutical Group Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shenzhen Hepalink Pharmaceutical Group Co 3-1 Month Momentum % vs Drug Manufacturers Industry
Shenzhen Hepalink Pharmaceutical Group Co (OTCPK:SHEZF) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a 3-1 Month Momentum % of N/A% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. According to the industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #560 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 54.6%.
Is Shenzhen Hepalink Pharmaceutical Group Co's 3-1 Month Momentum % too high?
Shenzhen Hepalink Pharmaceutical Group Co's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #560 out of 1025 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shenzhen Hepalink Pharmaceutical Group Co has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Hepalink Pharmaceutical Group Co's 3-1 Month Momentum % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shenzhen Hepalink Pharmaceutical Group Co ranks #560 out of 1025 companies for 3-1 Month Momentum %. This places Shenzhen Hepalink Pharmaceutical Group Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Shenzhen Hepalink Pharmaceutical Group Co and its competitors. Shenzhen Hepalink Pharmaceutical Group Co's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Hepalink Pharmaceutical Group Co stock overvalued right now?
Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is $0.51, compared to a current price of $0.47 — trading 7.9% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Shenzhen Hepalink Pharmaceutical Group Co's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Shenzhen Hepalink Pharmaceutical Group Co (SHEZF), the current 3-1 Month Momentum % is N/A% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shenzhen Hepalink Pharmaceutical Group Co (SHEZF) Overvalued in 2026?
Based on GuruFocus' analysis, Shenzhen Hepalink Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of $0.47 is trading 7.9% below its estimated GF Value™ of $0.51.
Key valuation signals for SHEZF:
3-1 Month Momentum %: N/A%
GF Value™: $0.51 vs. price of $0.47 (7.9% below fair value)
No single metric tells the full story. See the SHEZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company. Along with its subsidiary, it is engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development in Asia, Europe, North America, and Australia, and investment business in Asia and North America. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products; Active pharmaceutical ingredients; CDMO business; and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from Europe and the USA.
72GF Score
Get the complete analysis for SHEZF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHEZF has been successfully added to your 
